# Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT00492830** · PHASE1 · COMPLETED · sponsor: **Tracon Pharmaceuticals Inc.** · enrollment: 19 (actual)

## Conditions studied

- Cancer
- Neoplasm Metastasis

## Interventions

- **DRUG:** TRC093 recombinant humanized IgG1k monoclonal antibody

## Key facts

- **NCT ID:** NCT00492830
- **Lead sponsor:** Tracon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2010-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492830, "Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00492830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*